Introduction
Infection due to Cryptococcus neoformans, especially meningitis, is particularly a problem in patients with depressed cellular immunity, and this problem has been sharply exacerbated by the AIDS epidemic. 1 Standard antifungal therapy is commonly ineffective in the most severely immunosuppressed. 2 Evidence for an important role of interferon-gamma (IFN-␥) in the cell-mediated immune response includes development of anti-cryptococcal activity by IFN-␥ treatment of effector cells in vitro, [3] [4] [5] [6] [7] augmentation of cryptococcal infection in vivo by administration of antibody to IFN-␥ [8] [9] [10] [11] and reduction of cryptococcal infection by administration of IFN-␥. 9, 10, 12 We explored the effect of IFN-␥ alone, and in combination with different forms of antifungal therapy, in a murine model of systemic cryptococcosis that mimics the human disease. The treatments were prolonged, and were also designed to give insight into the effects of clinical treatment schedules.
Materials and methods

Mice
The animal experiments were approved by the institutional animal care and use committee. Male BALB/c mice 6-8 weeks old were infected and divided into groups of 9-12 per treatment regimen.
fluconazole by broth macrodilution testing was 1.56 and 6.25 mg/mL, respectively. 16 
Treatment regimens
Treatments commenced the day following infection. Amphotericin B deoxycholate suspension was given by the intraperitoneal (ip) route, 3 mg/kg thrice weekly for 2 weeks. Fluconazole by gavage in water and recombinant murine IFN-␥ (Genentech, South San Francisco, CA), 9.4 ϫ 10 6 U/mg, in saline, were given as detailed in Results. IFN-␥ every other day (qod) dosing is consistent with pharmacodynamic data. 17 Earlier experience in the model or preliminary experiments revealed ip deoxycholate alone or subcutaneous (sc) or iv saline produced the same results as no treatment. Mice were given sterilized food and acidified water ad libitum.
Organ infectious burden
One day after cessation of therapy, surviving mice were killed by CO 2 asphyxiation, and the livers and brains were removed, weighed and homogenized. Dilutions of the homogenates were placed on Sabouraud's agar plates with chloramphenicol, incubated at 35°C, and cfu/organ determined. The lower limit of sensitivity in this assay is 5-7 cfu/ organ. 14 
Statistics
Comparisons of infectious burdens between groups were performed using the Mann-Whitney U test. Mice that died of progressive infection during experiments were assigned for rank method significance testing a cfu value for infected organs, based on prior experiments in untreated mice dying of infection, higher than that in any surviving animal, to ensure that death was always scored as a worse outcome than survival with any burden of organisms. 13, 14 Fisher's exact test was performed to compare numbers of animals rendered infection-free in the groups. Significance was set at P Ͻ 0.05.
Results
Amphotericin and interferon
Experiment 1. IFN-␥ was given iv qod for 14 doses as therapy, or given prophylactically on days -7, -5, -3 and -1 before infection, or both.
Three of 10 infected untreated mice died before the end of the study period. Earlier experiments had demonstrated that residual infection in this model, with challenges of this size and this study duration, were р100 cfu in the kidney, lung or spleen, so subsequent studies focused on the heavily infected organs, the brain and the liver. The residual infection data are shown in Table I and the sterilization of infection in Table II . Amphotericin alone achieved a mean 23 000-fold reduction in cfu of C. neoformans from the brains of treated compared with untreated animals. IFN-␥ alone produced a 1.7-fold reduction of cfu in brain tissue, but this reduction was not significant. Amphotericin ϩ therapeutic IFN-␥ eliminated all brain infection, thus reducing brain infection Ͼ830 000-fold compared with controls, and also significantly (36-fold) compared with amphotericin alone (Table I) . Amphotericin ϩ prophylactic and therapeutic IFN-␥ eliminated brain infection in all but one animal, thus reducing the cfu of C. neoformans from brain tissue 350 000-fold compared with controls and also significantly (15-fold) compared with amphotericin alone. The cfu results obtained with amphotericin ϩ therapeutic IFN-␥ versus amphotericin ϩ prophylactic and therapeutic IFN-␥ were not significantly different. The IFN-␥ regimens: ther., therapeutic, given 100 000 U iv qod ϫ14 doses, starting 1 day post-infection; proph., prophylactic, given 100 000 U iv on days -7, -5, -3 and -1. Amphotericin: ip, 3 mg/kg, thrice weekly for 2 weeks. P values show Mann-Whitney U test comparisons. When treatment regimen (left of row) is superior to controls or amphotericin alone, the P value is indicated.
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number of mice whose brains were cleared of residual infection was significantly greater for those receiving amphotericin ϩ either IFN-␥ regimen (18/19 animals receiving any amphotericin-IFN-␥-containing regimen) compared with amphotericin alone (2/10) (Table II) . Amphotericin produced a significant, 2700-fold, reduction of liver infection compared with controls (Table I) . IFN-␥ significantly reduced infection, 0.05 log 10 . Compared with amphotericin alone, amphotericin ϩ therapeutic IFN-␥ reduced infection 2.3-fold, and amphotericin ϩ therapeutic and prophylactic IFN-␥ reduced it 2.8-fold, but neither improvement was significant. More livers were rendered free of detectable infection in both amphotericin-IFN-␥ groups compared with amphotericin alone, the trend was toward significance (P Ͻ 0.06 to Ͻ0.09).
The number of mice rendered free of detectable cryptococci in both organs, i.e. cured, was significantly greater for either amphotericin-IFN-␥ group compared with amphotericin alone (Table II) . The two combination groups were not significantly different from each other in comparing cure rates in either or both organs. Experiment 2, high inoculum. In a similar experiment, the inoculum was 25% higher, and the infection followed a more lethal course. There were only 2/12 (17%) survivors amongst the untreated controls, compared with 3/10 of those receiving therapeutic IFN-␥ and 5/10 of those receiving therapeutic ϩ prophylactic IFN-␥. All amphotericincontaining regimens produced 100% survival. Amphotericin alone, again significantly reduced infection in the brain (nine-fold) compared with the surviving controls (Table III) . Amphotericin ϩ therapeutic IFN-␥ produced a Ͼ100-fold reduction, and amphotericin ϩ therapeutic and prophylactic IFN-␥ an even greater 390-fold reduction. Both the combination regimens produced significantly better results than amphotericin alone, an 11-fold improvement for amphotericin ϩ therapeutic IFN-␥, and 43-fold improvement for amphotericin ϩ prophylactic and therapeutic IFN-␥. The latter combined regimen produced 3.8-fold better results than the former. IFN-␥ alone given prophylactically followed by a therapeutic dose regimen reduced infection 1.8-fold compared with controls, but therapeutic IFN-␥ alone was essentially the same as no treatment. Ther., therapeutic, given 100 000 U iv qod ϫ14 doses starting 1 day post-infection. Proph., prophylactic, given 100 000 U iv on days -7, -5, -3 and -1. P values show Mann-Whitney U test comparisons. Amphotericin: ip, 3 mg/kg, thrice weekly for 2 weeks. When treatment regimen (left of row) is superior to controls or amphotericin alone, the P value is indicated.
In the liver, amphotericin significantly reduced infection (150-fold) compared with controls (Table III) . While neither IFN-␥ regimen alone influenced the infection, they decreased the beneficial effect of amphotericin when administered in combination. In the case of therapeutic and prophylactic IFN-␥, this was a 10-fold difference and significant compared with amphotericin alone, or amphotericin ϩ therapeutic IFN-␥ (P ϭ 0.003). This IFN-␥ interference in the liver was opposite to the trend seen in the earlier experiment.
Experiment 3, route of IFN-␥.
Amphotericin was given alone or with IFN-␥ administered iv as previously or as sc doses. The infection was again highly lethal, with 90% mortality in control mice. All treatment groups survived (P Ͻ 0.01, compared with controls). The residual infection data are shown in Table IV . All three treatment regimens markedly reduced infection in both organs compared with controls (P Ͻ 0.001 for all six comparisons). Moreover, both combination regimens reduced (Ͼ100-fold) brain infection significantly compared with amphotericin alone (P Ͻ 0.05 for both comparisons). There was no evidence of IFN-␥ interference with amphotericin in the liver as seen in the second (but not the first) experiment.
Fluconazole and interferon
Initial IFN dose-finding experiment (data not shown). IFN was given sc qod for six doses of 2000, 10 000 or 50 000 U, alone or with 2.5 mg/kg fluconazole bid for 11 days. Fluconazole alone was effective in reducing geometric mean brain cfu from 5.58 to 3.65 log 10 (P Ͻ 0.01), but the regimens of IFN-␥ alone had no effect, and IFN-␥ did not potentiate fluconazole. Of interest, examining the liver cfu data, fluconazole treatment, with or without IFN-␥ (any dose), was worse than no treatment (P Ͻ 0.01 for all four comparisons), as was the lowest IFN-␥ dose alone, but IFN-␥ at the other two doses did not show this effect, and IFN-␥ at all three doses did not affect fluconazole.
Low dose fluconazole (data not shown).
A second experiment studied the same dose and number of treatments of IFN-␥, either iv or sc, as used in the amphotericin studies, and fluconazole 7.5 mg/kg/day for 17 days. The inoculum was 50% greater, and 70% of control animals died. Fluconazole ϩ IFN-␥ sc significantly prolonged survival (P Ͻ 0.05) compared with untreated control, and fluconazole alone (P ϭ 0.06), and fluconazole ϩ IFN-␥ iv (P ϭ 0.05) also prolonged survival to a lesser extent. Fluconazole ϩ IFN-␥ sc produced the greatest reduction in infection of the brain and liver (P ϭ 0.06 for both organs) compared with controls; this is in contrast to the adverse effect of the combination on the liver data in the previous experiment.
High-dose fluconazole.
A third experiment studied the same IFN regimens, and fluconazole at a 10 mg/kg/day dose for 17 days. All animals survived, and the residual infection data are shown in Table V . No animals were cleared of infection. Fluconazole, IFN-␥ sc, or IFN-␥ iv reduced brain infection significantly, and the fluconazole-IFN-␥ sc and fluconazole-IFN-␥ iv regimens did so to an even more marked degree. The combination regimens were superior to fluconazole alone, and to IFN-␥ alone (either combination P Ͻ 0.01 versus IFN-␥ alone sc, and P Ͻ 0.05 versus IFN alone iv). IFN-␥ alone, either route, produced a significant reduction in cfu from the liver as compared with the controls. For a third time, fluconazole was ineffective in reducing the burden of infection in the liver, and was also inferior to IFN-␥ alone (either route; IFN-␥ sc and IFN-␥ iv versus fluconazole, P Ͻ 0.05 and Ͻ0.01, respectively). Fluconazole did not enhance the effect of IFN-␥ (combination fluconazole-IFN-␥ was not superior to IFN-␥ alone), neither did it demonstrate an antagonistic effect (both fluconazole-IFN-␥ combination regimens were significantly superior to fluconazole alone).
Discussion
These studies show a modest efficacy of IFN-␥ given therapeutically alone, and an impressive potentiation of ampho- tericin therapy, in reducing infection in the most important site of infection in this murine model (and in the human disease), the central nervous system. The efficacy was seen in lethal and non-lethal challenges, and when IFN-␥ was given by the iv or sc route. In a non-lethal infection, only the combination of amphotericin ϩ IFN-␥ (not either component alone) produced the most desirable and profound result of all, sterilization of the central nervous system. Potentiation of fluconazole was less impressive. Adding prophylactic doses of IFN-␥ to IFN-␥ therapy did not consistently enhance the therapeutic effect. IFN-␥ often showed efficacy in reducing liver infection, but effects in this organ were not consistent. These results corroborate and extend the observations of Joly et al. 12 in mice, who studied short course regimens of rat IFN-␥ (three doses, two given prophylactically) and amphotericin (one dose). They showed prolongation of survival by IFN-␥ alone and potentiation of amphotericin therapy, reduction of brain infection by the combination regimen, but not sterilization. Our sub-acute model and prolonged therapy more closely mimics the human disease and its therapy.
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Murine macrophages stimulated in vitro with rIFN-␥ suppress growth of extracellular cryptococci, 3 apparently by an extracellular stimulated macrophage product. IFN-␥ alone had no growth-inhibitory effect. Opsonized cryptococci can be killed intracellularly by murine macrophages activated by rIFN-␥ in vitro or in vivo. 6 Differences in the capacity to kill encapsulated and non-encapsulated cryptococci have been noted. 6 Rat rIFN-␥-treated rat alveolar macrophages inhibit growth of cryptococci by a mechanism involving increased adhesion or uptake.
7 IFN-␥ is involved in activating human astrocytes, 5 but not microglia, 18 to kill cryptococci and in enhancing anti-cryptococcal activity of mixed lymphocyte populations from HIV-infected persons. 4 Treatment of mice with a monoclonal antibody against IFN-␥ enhanced their susceptibility to pulmonary 9,10 or systemic 11 challenge, and this also occurs in immune animals. 8 Amphotericin can prime macrophages for a second signal from IFN-␥, producing an enhanced oxidative burst. 19, 20 IFN-␥ and amphotericin interacted cooperatively in murine macrophages to eradicate ingested cryptococci, whereas fluconazole and IFN-␥ did not. 21 Intraperitoneal rIFN-␥ significantly prolonged survival of mice challenged intra-tracheally with C. neoformans. 9, 10 Interleukin-12, a potent stimulator of IFN-␥ production, enhances host resistance against systemic cryptococcal challenge and potentiates fluconazole therapy. 22 Others have corroborated this, 23 and shown that the effect is mediated by IFN-␥.
Taken together, these in vitro and in vivo results, and our results, indicate that IFN-␥ potentiates conventional antifungal therapy, particularly amphotericin. This argues for further studies of the possible mechanisms of this potentiation and for exploration of this beneficial effect in the clinical setting. This enhancement may be most critical in the patient with a marginal endogenous response to infection, the immunocompromised patient, who is so susceptible to cryptococcal disease. However, more experimental evidence addressing this particular question would be of interest; one must always also be cautious in extrapolating conclusions from experimental systems into the clinic. 24 If adjunctive IFN-␥ therapy could allow shorter courses or lower doses of amphotericin, reducing the potential for amphotericin toxicity and/or shortening the duration of the patient's hospital stay, this would also be an important benefit. 
